Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Cosmeri Rizzato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7830-2178; OpenAlex author ID A5059413640. Sources: OpenAlex.

Their work

Papers
27 (first author 5, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 3 papers · 2025: 9 papers · 2026: 1 paper

Papers 27

  1. Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet? First author DOI 10.17235/reed.2026.12183/2026↗
  2. Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort. Co-author DOI 10.1002/ueg2.70102↗
  3. Genetic landscape for screening and early diagnosis of pancreatic ductal adenocarcinoma: is there a signature? Last author DOI 10.1016/j.bpg.2025.101988↗
  4. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.02.009↗
  5. The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.03.002↗
  6. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Last author DOI 10.1016/j.semcancer.2025.05.004↗
  7. Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.05.005↗
  8. Therapeutic pancreatic cancer biomarkers and pharmacogenetics. Co-author DOI 10.1016/j.semcancer.2025.08.002↗
  9. Long or short? Telomere length and pancreatic cancer and its precursor lesions, a narrative review. Last author DOI 10.1093/mutage/gead034↗
  10. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  11. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  12. Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study. Co-author DOI 10.1038/s41598-024-77431-5↗
  13. Publisher Correction: Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomi… Co-author DOI 10.1038/s41598-024-83618-7↗
  14. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  15. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  16. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  17. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  18. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  19. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  20. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  21. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. First author DOI 10.1002/ijc.29590↗
  22. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  23. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. First author DOI 10.1038/ng.3052↗
  24. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. First author DOI 10.1016/j.dld.2012.09.014↗
  25. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. First author DOI 10.1158/1055-9965.epi-12-1182↗
  26. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗
  27. Pancreatic cancer susceptibility loci and their role in survival. Co-author DOI 10.1371/journal.pone.0027921↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniele Campa · 18 shared papers, 2011–2026 · strength 3.16
  2. Riccardo Farinella · 7 shared papers, 2023–2025 · strength 1.53
  3. Manuel Gentiluomo · 5 shared papers, 2023–2025 · strength 1.25
  4. Federico Canzian · 10 shared papers, 2011–2025 · strength 1.00
  5. Giulia Peduzzi · 4 shared papers, 2025 · strength 0.94
  6. David J. Hughes · 5 shared papers, 2017–2025 · strength 0.90
  7. Neil Daniel · 4 shared papers, 2024–2025 · strength 0.86
  8. Pavel Souček · 7 shared papers, 2013–2025 · strength 0.66
  9. William Greenhalf · 5 shared papers, 2011–2026 · strength 0.60
  10. Gabriele Capurso · 7 shared papers, 2013–2025 · strength 0.59
  11. Ľudmila Vodičková · 6 shared papers, 2013–2025 · strength 0.53
  12. Pavel Vodička · 6 shared papers, 2013–2025 · strength 0.53
  13. Salvatore Paiella · 2 shared papers, 2025–2026 · strength 0.53
  14. Lívia Archibugi · 2 shared papers, 2025 · strength 0.48
  15. Chiara Corradi · 2 shared papers, 2023–2025 · strength 0.44
  16. Pinar Uysal Onganer · 2 shared papers, 2025 · strength 0.37
  17. Beatrice Mohelníková-Duchoňová · 5 shared papers, 2013–2025 · strength 0.37
  18. Julie Earl · 1 shared paper, 2026 · strength 0.36
  19. Stefano Landi · 5 shared papers, 2013–2025 · strength 0.32
  20. Eithne Costello · 4 shared papers, 2011–2025 · strength 0.24
  21. Ștefania Bunduc · 1 shared paper, 2025 · strength 0.24
  22. Michal Kroupa · 1 shared paper, 2025 · strength 0.24
  23. Viktor Hlaváč · 1 shared paper, 2025 · strength 0.24
  24. Aleš Langer · 1 shared paper, 2025 · strength 0.24
  25. Kari Hemminki · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.